Study Rationale and Design of a Study of Empagliflozin's Effects in Patients With Type 2 Diabetes Mellitus and Coronary ARtery Disease: The EMPA-CARD Randomized Controlled Trial release_hivp5rsgkvd33ov6uwi3p4l3ri

by Sepehr Gohari, Tara Reshadmanesh, Hadi Khodabandehloo, Mojtaba Fathi, hassan ahangar, Shahram Arsang-Jang, Faramarz Ismail-Beigi, Samin Ghanbari, Mohsen Dadashi, Muhammad Javad Muhammadi, Sheida Gohari, Saeid Ghaffari

Released as a post by Research Square.

2020  

Abstract

<jats:title>Abstract</jats:title> Background: Recent trials have revealed that sodium-glucose co-transporter 2 inhibitors (SGLT2-i) are effective against hyperglycemia and also reduce micro- and macro-vascular complications in patients with type 2 diabetes mellitus (T2DM). Most of the beneficial cardiovascular effects have been investigated in patients with heart failure and coronary artery disease (CAD). Yet, no human study has been conducted to investigate the mechanisms underlying these clinically beneficial effects in patients with CAD. Accordingly, the EMPA-CARD trial was designed to focus on the molecular effects of empagliflozin in patients with T2DM and CAD.Methods: In this multicenter, triple-blind randomized controlled trial, patients with documented known T2DM and CAD will be recruited. They will be randomized on a 1:1 ratio and assigned into two groups of empagliflozin 10 mg/daily and placebo. The primary endpoint is the effect of empagliflozin on changes of plasma interleukin 6 (IL-6) after 26 weeks of treatment. The secondary endpoints will consist of changes in other inflammatory biomarkers (Interleukin 1-beta and high-sensitive C-reactive protein), markers of oxidative stress, platelet function, and glycemic status. Discussion: The EMPA-CARD trial mainly tests the hypothesis that SGLT2 inhibition by empagliflozin may improve inflammatory status measured as reduction in inflammatory biomarkers in patients with T2DM and CAD. The results will provide information about the underlying mechanisms of SGLT2 inhibition that mediate the beneficial effects of this medication on clinical outcomes.Trial registration: Iranian Registry of Clinical Trials. www.IRCT.ir, Identifier: IRCT20190412043247N2. Registration Date: 6/13/2020. Registration timing: prospective
In application/xml+jats format

Archived Files and Locations

application/pdf   367.1 kB
file_sv7emqohcrbchjaid2skbkz7zi
assets.researchsquare.com (publisher)
web.archive.org (webarchive)
application/pdf   527.3 kB
file_nxb2yjtqbzdvzn5t5o6q4p3jfy
assets.researchsquare.com (web)
web.archive.org (webarchive)
Read Archived PDF
Preserved and Accessible
Type  post
Stage   unknown
Date   2020-12-10
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: a4e1fcd1-ebbf-415f-81c5-73a580645814
API URL: JSON